Our Services

Our manufacturing and quality team cover medical devices, diagnostics, biologics and small molecules. Our team have held senior positions with key responsibilities and experiences including:

  • head of a Medical Notified Body, responsible for planning, delivery and periodic review of effectiveness of certification service lines
  • completing over 300 worldwide medical device and in vitro diagnostics audits
  • preparing 510k submissions for in vitro diagnostics and active and non-active, sterile and non-sterile devices
  • preparing technical files for CE marking for varying medical devices & in vitro diagnostics
  • Qualified Person and Head of Quality for a leading biologics developer, having responsibility for ensuring quality throughout the organisation, from research through development to clinical trials, encompassing GLP, GMP and GCP
  • applying broad experience in the manufacture and control of both terminally sterilized and aseptically prepared sterile pharmaceuticals, including ophthalmic products, lyophilized products, and creams and lotions, as well as most non-sterile dosage forms

Alacrita’s team also has expertise in preclinical and CMC, for example building multi-disciplinary CMC development groups, composing expert reports and quality overall summaries for EU filings. We have even been designated as “Experts” in CMC filings.

Case study: Providing pharma manufacturing consultancy during and after a buy-out


A large European biotech company had purchased a UK-based biotech company that was in the early stages of developing a potential breakthrough drug for treating arthritis. The parent company needed support in delivering the development programme during this transition.


Our CMC consultant worked with the company to deliver across a broad range of areas, including:

  • drug substance manufacture, characterization and salt selection, developing of assays and stability testing
  • formulation strategy and design to overcome poor bioavailability in both animals and humans
  • regulatory submission for first-in-man studies, including a scientific advice meeting with the MHRA (Medicines and Healthcare Regulatory Agency)
  • transferring manufacturing of drug substance and product between different sites and chief research officers
  • a review of all manufacturing activities covering a period of five years
  • a pharmaceutical and toxicological assessment for a regulatory scientific advice meeting, which had been prompted by the presence of a genotoxic impurity in an early batch of drug substance
  • establishing and maintaining the development archive for the project and then transferring this to the new client’s head office
  • due diligence activities

Further case studies regarding Manufacturing are available here.

Related Case Studies

Stay in touch